Corealis Pharma Marks 20 Years

WITH NEW LEADERSHIP AND EXPANDED HORIZONS

THIS FALL, COREALIS PHARMA proudly celebrates its 20th anniversary, a milestone that underscores two decades of scientific rigor, innovation and commitment to supporting biotechnology and pharmaceutical innovators bringing life-changing therapies to patients worldwide.

Headquartered in Laval, Quebec, Corealis has remained steadfast in its core expertise: the development and manufacturing of oral solid dose (OSD) formulations. The company has built a reputation as a trusted CDMO partner by delivering purpose-built solutions that ensure stability, compatibility and optimized bioavailability for some of the industry’s most challenging molecules. While its foundation has remained strong, Corealis has also embraced growth. In 2024, the company doubled its capacity, an expansion that strengthens its ability to support clients navigating increasingly complex pipelines.

As Corealis continues its path of transformation and progress, it enters an exciting new chapter of leadership. David Leroux-Petersen has been appointed CEO, bringing both strategic vision and deep operational expertise. David is no stranger to the life science industry and will focus his leadership on building upon the company’s scientific excellence and client centricity, while charting the course for future innovation.

Corealis also takes this opportunity to recognize the outstanding contributions of former President Yves Roy as he takes his retirement. Under his stewardship, Corealis not only weathered the challenges of a rapidly evolving industry but emerged with an expanded scale and unwavering commitment to client success. Co-Founders Yves Mouget and Patrick Gosselin remain actively engaged in their leadership roles, working closely with CEO David Leroux-Petersen to ensure continuity of vision, culture and strategic direction. The management team has also welcomed Pascal Tougas as Chief Financial Officer. Pascal brings deep financial expertise and industry insight from his tenure at Sanofi.

The road ahead is paved with exciting opportunities. More complex active pharmaceutical ingredients (APIs) are entering pipelines, requiring specialized formulation strategies to achieve solubility, stability and target bioavailability. Corealis is uniquely positioned to meet these challenges with scaled infrastructure, focused oral solid dose expertise and a committed talented team.

The numbers speak volumes: over 900 projects successfully executed between 2020 and 2025 with 100% on-time delivery, more than 25 drug approvals reaching over 100,000 patients worldwide, and commercial products generating in excess of $10 billion in annual revenue for clients. These achievements are the direct result of Corealis’ scientific expertise, client-centric approach and dedication to advancing therapeutics.

As Corealis Pharma celebrates its 20th year, the company looks forward with renewed energy and a commitment to continued excellence. With expanded capacity, new leadership, continued portfolio investments and a sharpened focus on solving the most complex formulation challenges, the future ahead promises to be its most impactful yet.